Abstract
The most common side effect of opioids is opioid-induced constipation (OIC). No drug is specifically approved currently for treatment of OIC in patients receiving opioids for chronic non-malignant pain. Subcutaneous (SC) methylnaltrexone decreases constipating effects of opioids without affecting central analgesia. We report additional efficacy results from the double-blind phase of a randomized, placebo-controlled study of methylnaltrexone in patients taking opioids for chronic non-malignant pain.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
